Synthetic Heparins as Safe Disease-modifying Drugs for Early-Stage Treatment of AD via Inhibition of Beta-Secretase: Evaluation in a Transgenic Mouse Model

Research Categorization
Researcher and Organization
Principal Investigator
Principal Investigator First Name
Jerry
Principal Investigator Last Name
Turnbull
Awardee Organization
Contact PI Country
Project Detail
Funding Opportunity Announcement
FY Overall Cost
$261,235
Funding Organization
Agency/Funding Organization
Funding Organization Country